

CITATION REPORT

List of articles citing

Quantitative signal detection using spontaneous ADR reports

DOI: 10.1002/pds.1742

Pharmacoepidemiology and Drug Safety, 2009, 18, 427-36.

Source: <https://exaly.com/paper-pdf/46293245/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
471	Signal Detection of Drug Complications Applying Association Rule Learning for Stevens-Johnson Syndrome. 2009 , 10, 118-127		5
470	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2009 , 18, i-xii	2.6	
469	Schutzimpfung gegen Rotavirusgastroenteritis. 2010 , 158, 1253-1260		4
468	Mining multi-item drug adverse effect associations in spontaneous reporting systems. 2010 , 11 Suppl 9, S7		115
467	Selected control events and reporting odds ratio in signal detection methodology. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 1159-65	2.6	23
466	A potential competition bias in the detection of safety signals from spontaneous reporting databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, 1166-71	2.6	36
465	Current issues in drug regulation. 2010 , 19-31		
464	Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. <i>Drug Safety</i> , 2010 , 33, 303-14	5.1	94
463	Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation. <i>Drug Safety</i> , 2010 , 33, 417-34	5.1	8
462	Mapping the safety profile of biologicals: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. <i>Drug Safety</i> , 2010 , 33, 865-78	5.1	31
461	Maintaining and Enhancing the Value of Spontaneous Reporting Programmes. 2011 , 25, 83-86		3
460	New approaches to strengthen pharmacovigilance. 2011 , 8, e1-e42		8
459	Hypersensitivity reactions to anticancer agents: data mining of the public version of the FDA adverse event reporting system, AERS. 2011 , 30, 93		57
458	Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. 2011 , 22, 1170-1180		237
457	Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS. 2011 , 8, 332-8		27
456	Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. 2011 , 8, 487-91		40
455	Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system. 2011 , 6, e28124		50

454	Can network analysis improve pattern recognition among adverse events following immunization reported to VAERS?. 2011 , 90, 271-8		33
453	When to publish measures of disproportionality derived from spontaneous reporting databases?. <i>British Journal of Clinical Pharmacology</i> , 2011 , 72, 909-11	3.8	17
452	Biclustering of adverse drug events in the FDA's spontaneous reporting system. 2011 , 89, 243-50		58
451	Detecting drug interactions from adverse-event reports: interaction between paroxetine and pravastatin increases blood glucose levels. 2011 , 90, 133-42		161
450	Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. <i>International Journal of Clinical Pharmacy</i> , 2011 , 33, 806-14	2.3	28
449	Multinomial modeling and an evaluation of common data-mining algorithms for identifying signals of disproportionate reporting in pharmacovigilance databases. 2012 , 28, 3123-30		12
448	Data mining methodologies for pharmacovigilance. 2012 , 14, 35-42		15
447	Comparison of rates of reported adverse events associated with i.v. iron products in the United States. 2012 , 69, 310-20		61
446	Adverse Reaction Signaling and Disproportionality Analysis: An Update. 2012 , 46, 708-714		4
445	The coming age of data-driven medicine: translational bioinformatics' next frontier. 2012 , 19, e2-4		62
444	INDI: a computational framework for inferring drug interactions and their associated recommendations. 2012 , 8, 592		131
443	Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. 2012 , 35, 967-70		44
442	Data-driven prediction of drug effects and interactions. 2012 , 4, 125ra31		410
441	Comparing data-mining algorithms developed for longitudinal observational databases. 2012 ,		2
440	Systems Approach to Patient Safety. 2012 , 583-597		1
439	Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. <i>Drug Safety</i> , 2012 , 35, 315-23	5.1	29
438	Identifying adverse events of vaccines using a Bayesian method of medically guided information sharing. <i>Drug Safety</i> , 2012 , 35, 61-78	5.1	9
437	Vaccine-based subgroup analysis in VigiBase: effect on sensitivity in paediatric signal detection. <i>Drug Safety</i> , 2012 , 35, 335-46	5.1	11

436	Terminological challenges in safety surveillance. <i>Drug Safety</i> , 2012 , 35, 79-84	5.1	11
435	A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. <i>Drug Safety</i> , 2012 , 35, 599-610	5.1	16
434	Novel data-mining methodologies for adverse drug event discovery and analysis. 2012 , 91, 1010-21		230
433	iADRs: towards online adverse drug reaction analysis. 2012 , 1, 72		4
432	Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. 2012 , 9, 441-6		29
431	Omeprazole- and esomeprazole-associated hypomagnesaemia: data mining of the public version of the FDA Adverse Event Reporting System. 2012 , 9, 322-6		29
430	Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. 2012 , 9, 33-9		41
429	Signal detection to identify serious adverse events (neuropsychiatric events) in travelers taking mefloquine for chemoprophylaxis of malaria. 2012 , 4, 87-92		4
428	A shrinkage-based comparative assessment of observed-to-expected disproportionality measures. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 589-96	2.6	7
427	Using time-to-onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study. <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 603-10	2.6	28
426	Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). <i>Pharmacoepidemiology and Drug Safety</i> , 2012 , 21, 1216-20	2.6	52
425	A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reports. 2012 , 19, 79-85		133
424	ABCDXXX: The obscurity of postmarketing surveillance for teratogenic effects. 2012 , 94, 670-6		11
423	Implementation of an automated signal detection method in the French pharmacovigilance database: a feasibility study. 2012 , 68, 793-9		8
422	Annotation Analysis for Testing Drug Safety Signals using Unstructured Clinical Notes. 2012 , 3 Suppl 1, S5		66
421	Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine. <i>Drug Safety</i> , 2013 , 36, 547-56	5.1	28
420	Antipsychotics and torsadogenic risk: signals emerging from the US FDA Adverse Event Reporting System database. <i>Drug Safety</i> , 2013 , 36, 467-79	5.1	53
419	How do patients contribute to signal detection? : A retrospective analysis of spontaneous reporting of adverse drug reactions in the UK's Yellow Card Scheme. <i>Drug Safety</i> , 2013 , 36, 199-206	5.1	65

418	An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. <i>Drug Safety</i> , 2013 , 36, 119-34	5.1	52
417	The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. 2013 , 50, 569-77		79
416	Web-scale pharmacovigilance: listening to signals from the crowd. 2013 , 20, 404-8		147
415	Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database. 2014 , 51, 491-7		44
414	Profiling adverse drug events of cancer drug ingredients using normalized AERS data. 2013 ,		
413	Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. 2013 , 93, 539-46		168
412	Pharmacovigilance using clinical notes. 2013 , 93, 547-55		119
411	Data mining for signal detection of adverse event safety data. 2013 , 23, 146-60		6
410	Adverse drug events: database construction and in silico prediction. 2013 , 53, 744-52		97
409	Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. 2013 , 20, 413-9		117
408	Creation and implementation of a historical controls database from randomized clinical trials. 2013 , 20, e162-8		16
407	Empirical bayes model to combine signals of adverse drug reactions. 2013 ,		12
406	Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1119-29	2.6	19
405	Optimization of a quantitative signal detection algorithm for spontaneous reports of adverse events post immunization. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 477-87	2.6	7
404	Disproportionality methods for pharmacovigilance in longitudinal observational databases. 2013 , 22, 39-56		68
403	Tumor necrosis factor antagonist-associated psoriasis in inflammatory diseases: an analysis of the FDA adverse event reporting system. 2013 , 19, 1164-72		25
402	A survey of the FAERS database concerning the adverse event profiles of β -adrenoreceptor blockers for lower urinary tract symptoms. 2013 , 10, 864-9		19
401	Special Applications of Pharmacoepidemiology. 2013 , 337-406		

400	Pneumothorax as an adverse drug event: an exploratory aggregate analysis of the US FDA AERS database including a confounding by indication analysis inspired by Cornfield's condition. 2013 , 10, 965-73		9
399	Drug Adverse Event Detection in Health Plan Data Using the Gamma Poisson Shrinker and Comparison to the Tree-based Scan Statistic. 2013 , 5, 179-200		15
398	Comparison of the safety of seven iodinated contrast media. 2013 , 28, 1703-10		25
397	Data mining of the public version of the FDA Adverse Event Reporting System. 2013 , 10, 796-803		234
396	Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. 2014 , 3, e02523		723
395	Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms. 2014 , 11, 461-5		7
394	Quantitative Signal Detection and Analysis in Pharmacovigilance. 2014 , 331-354		10
393	A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 853-7	4.1	14
392	Signal detection on spontaneous reports of adverse events following immunisation: a comparison of the performance of a disproportionality-based algorithm and a time-to-onset-based algorithm. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 178-85	2.6	15
391	The upper bound to the Relative Reporting Ratio—a measure of the impact of the violation of hidden assumptions underlying some disproportionality methods used in signal detection. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 787-94	2.6	5
390	A conceptual approach to the masking effect of measures of disproportionality. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 208-17	2.6	12
389	Channeling postmarketing patient data into pharmaceutical regulatory systems. 2014 , 19, 1897-912		1
388	Investigating the accuracy of the openFDA API using the FDA Adverse Event Reporting System (FAERS). 2014 ,		2
387	Signalling paediatric side effects using an ensemble of simple study designs. <i>Drug Safety</i> , 2014 , 37, 163-70		7
386	Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. 2014 , 14, 17		8
385	Large-scale combining signals from both biomedical literature and the FDA Adverse Event Reporting System (FAERS) to improve post-marketing drug safety signal detection. 2014 , 15, 17		50
384	AERS spider: an online interactive tool to mine statistical associations in Adverse Event Reporting System. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 795-801	2.6	8
383	Regulatory decision-making: are we getting it right?. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 1012-6	2.6	1

382	Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events. 2014 , 39, 307-13		15
381	Zoo or savannah? Choice of training ground for evidence-based pharmacovigilance. <i>Drug Safety</i> , 2014 , 37, 655-9	5.1	32
380	A method for controlling complex confounding effects in the detection of adverse drug reactions using electronic health records. 2014 , 21, 308-14		30
379	Dose-specific adverse drug reaction identification in electronic patient records: temporal data mining in an inpatient psychiatric population. <i>Drug Safety</i> , 2014 , 37, 237-47	5.1	48
378	Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database. 2014 , 34, 5-13		31
377	Disease-related adverse events following non-live vaccines: investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase. 2014 , 32, 3328-35		1
376	Pharmacoepidemiological characterization of drug-induced adverse reaction clusters towards understanding of their mechanisms. 2014 , 50, 50-9		7
375	Automatic signal extraction, prioritizing and filtering approaches in detecting post-marketing cardiovascular events associated with targeted cancer drugs from the FDA Adverse Event Reporting System (FAERS). 2014 , 47, 171-7		29
374	Association of statin use with sleep disturbances: data mining of a spontaneous reporting database and a prescription database. <i>Drug Safety</i> , 2014 , 37, 421-31	5.1	32
373	Pilot evaluation of an automated method to decrease false-positive signals induced by co-prescriptions in spontaneous reporting databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2014 , 23, 186-94	2.6	7
372	[Evaluation of the association between the use of oral anti-hyperglycemic agents and hypoglycemia in Japan by data mining of the Japanese Adverse Drug Event Report (JADER) database]. 2014 , 134, 299-304		14
371	Detecting associations between behavioral addictions and dopamine agonists in the Food & Drug Administration's Adverse Event database. 2014 , 3, 21-6		8
370	Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database. 2015 , 38, 680-6		41
369	Analysis of Neuropsychiatric Adverse Events in Patients Treated with Oseltamivir in Spontaneous Adverse Event Reports. 2015 , 38, 1638-44		20
368	Identification of sex-associated network patterns in Vaccine-Adverse Event Association Network in VAERS. 2015 , 6, 33		3
367	Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports. 2015 , 1, 15		21
366	Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China. <i>Pharmacoepidemiology and Drug Safety</i> , 2015 , 24, 962-70	2.6	1
365	Effect of reporting bias in the analysis of spontaneous reporting data. 2015 , 14, 20-5		12

364	Systems pharmacology augments drug safety surveillance. 2015 , 97, 151-8		32
363	Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database. 2015 , 12, 135-40		28
362	Role of Pharmacovigilance in India: An overview. 2015 , 7, e223		24
361	Association between statin use and cancer: data mining of a spontaneous reporting database and a claims database. 2015 , 12, 223-33		31
360	Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age. 2015 , 12, 312-21		20
359	Update on Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on QT Interval, Left Ventricular Dysfunction and Overall Risk/Benefit. <i>Drug Safety</i> , 2015 , 38, 693-710	5.1	79
358	Automagically Encoding Adverse Drug Reactions in MedDRA. 2015 ,		8
357	A Systematic Prediction of Adverse Drug Reactions Using Pre-clinical Drug Characteristics and Spontaneous Reports. 2015 ,		4
356	A research framework for pharmacovigilance in health social media: Identification and evaluation of patient adverse drug event reports. 2015 , 58, 268-279		39
355	Extraction of Clinical Phenotypic Information from Online Heterogeneous Healthcare Networks. 2015 ,		
354	Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. 2015 , 55, 768-73		8
353	Combining automatic table classification and relationship extraction in extracting anticancer drug-side effect pairs from full-text articles. 2015 , 53, 128-35		9
352	Portable automatic text classification for adverse drug reaction detection via multi-corpus training. 2015 , 53, 196-207		206
351	Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System. 2015 , 90, E66-72		42
350	Reporting patterns of adverse drug reactions over recent years in China: analysis from publications. <i>Expert Opinion on Drug Safety</i> , 2015 , 14, 191-8	4.1	17
349	Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. <i>British Journal of Clinical Pharmacology</i> , 2015 , 80, 285-93	3.8	53
348	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. 2015 , 229, 257-63		10
347	A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. <i>Drug Safety</i> , 2015 , 38, 895-908	5.1	38

346	Publisher's Note: Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction. 2015 , 58, 104-19		2
345	Methods for observational post-licensure medical product safety surveillance. 2015 , 24, 177-93		15
344	Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. <i>Drug Safety</i> , 2015 , 38, 1201-10	5.1	34
343	Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database. 2015 , 29, 879-91		9
342	Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database. <i>Drug Safety</i> , 2015 , 38, 1127-39	5.1	5
341	Reprint of "Abstraction for data integration: Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction". 2015 , 59 Pt B, 123-38		9
340	Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase. 2015 , 49, 1197-206		28
339	Paraesthesia after local anaesthetics: an analysis of reports to the FDA Adverse Event Reporting System. 2015 , 117, 52-6		17
338	Methods and Issues to Consider for Detection of Safety Signals From Spontaneous Reporting Databases: A Report of the DIA Bayesian Safety Signal Detection Working Group. 2015 , 49, 65-75		6
337	Comparison of two drug safety signals in a pharmacovigilance data mining framework. 2016 , 25, 615-29		3
336	Patterns of adverse drug reaction signals in NAFDAC Pharmacovigilance activities from September to November, 2014. <i>International Journal of Risk and Safety in Medicine</i> , 2016 , 28, 13-23	1.6	2
335	Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature. 2016 , 17, 250		9
334	Using Rich Data on Comorbidities in Case-Control Study Design with Electronic Health Record Data Improves Control of Confounding in the Detection of Adverse Drug Reactions. 2016 , 11, e0164304		6
333	Signal Detection of Adverse Drug Reaction of Amoxicillin Using the Korea Adverse Event Reporting System Database. 2016 , 31, 1355-61		11
332	The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 297-306	2.6	7
331	Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. <i>Clinical Drug Investigation</i> , 2016 , 36, 735-742	3.2	31
330	Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). 2016 , 31, 336-40		55
329	Publicity and reports of behavioral addictions associated with dopamine agonists. 2016 , 5, 140-143		8

328	Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 583-90	4.1	14
327	MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4. 2016 , 5, 51-6		21
326	Data Mining of the US FDA Adverse Events Reporting System Database to Evaluate Drug-Drug Interactions Associated with Statin-Induced Rhabdomyolysis. 2016 , 30, 327-337		1
325	The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 1361-1367	2.6	8
324	Improving drug safety: From adverse drug reaction knowledge discovery to clinical implementation. 2016 , 110, 14-25		20
323	[Analysis of Spontaneously Reported Adverse Events]. 2016 , 136, 549-56		5
322	Outcome of antiepileptic drug treatment of 1282 patients with epilepsy, their pharmacovigilance reports and concomitant medication on CNS in an East-Hungarian adult database. 2016 , 369, 220-226		7
321	Quetiapine adverse events in older adults in Australia. 2016 , 35, 281-284		5
320	Early identification of adverse drug reactions from search log data. 2016 , 59, 42-8		33
319	Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification. <i>Drug Safety</i> , 2016 , 39, 873-81	5.1	9
318	Improving drug safety with a systems pharmacology approach. 2016 , 94, 84-92		15
317	Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 1003-11	4.1	59
316	Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. 2016 , 56, 769-78		9
315	Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database. 2016 , 2, 14		42
314	The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project. <i>Drug Safety</i> , 2016 , 39, 59-68	5.1	22
313	Toxicological Differences Between NMDA Receptor Antagonists and Cholinesterase Inhibitors. 2016 , 31, 405-12		13
312	Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias: A Disproportionality Analysis Using Data from Vigibase(®). <i>Drug Safety</i> , 2016 , 39, 689-96	5.1	23
311	An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval. <i>Drug Safety</i> , 2016 , 39, 433-41	5.1	26

310	OpenFDA: an innovative platform providing access to a wealth of FDA's publicly available data. 2016 , 23, 596-600		28
309	A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports. <i>Drug Safety</i> , 2016 , 39, 561-75	5.1	29
308	Good Signal Detection Practices: Evidence from IMI PROTECT. <i>Drug Safety</i> , 2016 , 39, 469-90	5.1	65
307	In silico assessment of adverse drug reactions and associated mechanisms. 2016 , 21, 58-71		34
306	Use of data mining at the Food and Drug Administration. 2016 , 23, 428-34		67
305	Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme. <i>Clinical Drug Investigation</i> , 2017 , 37, 259-272	3.2	36
304	Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1532-1543	3.8	19
303	Signal Detection Based on Time to Onset Algorithm in Spontaneous Reporting System of China. <i>Drug Safety</i> , 2017 , 40, 343-350	5.1	2
302	Utilization of chi-square statistics for screening adverse drug-drug interactions in spontaneous reporting systems. 2017 , 73, 779-786		10
301	Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?. <i>Clinical Drug Investigation</i> , 2017 , 37, 415-422	3.2	32
300	A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms. <i>Drug Safety</i> , 2017 , 40, 517-530	5.1	6
299	Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports. 2017 , 76, 7-15		42
298	Biomedical Informatics Approaches to Identifying Drug-Drug Interactions: Application to Insulin Secretagogues. 2017 , 28, 459-468		16
297	Detecting Signals of Disproportionate Reporting from Singapore's Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test. <i>Drug Safety</i> , 2017 , 40, 703-713 ^{5.1}		4
296	The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. 2017 , 8, 145-156		7
295	Data-mining for detecting signals of adverse drug reactions of fluoxetine using the Korea Adverse Event Reporting System (KAERS) database. 2017 , 256, 237-242		18
294	Disproportionality analysis of buprenorphine transdermal system and cardiac arrhythmia using FDA and WHO postmarketing reporting system data. 2017 , 129, 62-68		8
293	Novel adverse events of vortioxetine: A disproportionality analysis in USFDA adverse event reporting system database. 2017 , 30, 152-156		7

292	Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1164-1171	2.6	15
291	Assessment of a Severity-Based Algorithm to Detect Signals of Severe Drug-Induced Liver Injury Using Spontaneous Reporting Database. 2017 , 31, 41-51		
290	vigiRank for statistical signal detection in pharmacovigilance: First results from prospective real-world use. <i>Pharmacoepidemiology and Drug Safety</i> , 2017 , 26, 1006-1010	2.6	17
289	Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. 2017 , 12, e0185654		27
288	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. 2017 , 18,		3
287	Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database. 2017 , 58, 564-569		11
286	A mathematical framework to quantify the masking effect associated with the confidence intervals of measures of disproportionality. 2017 , 8, 231-244		7
285	The hope, hype and reality of Big Data for pharmacovigilance. 2018 , 9, 5-11		23
284	In silico profiling of systemic effects of drugs to predict unexpected interactions. <i>Scientific Reports</i> , 2018 , 8, 1612	4.9	6
283	Sources of Safety Data and Statistical Strategies for Design and Analysis: Postmarket Surveillance. 2018 , 52, 159-169		11
282	Hepatitis B infection reported with cancer chemotherapy: analyzing the US FDA Adverse Event Reporting System. 2018 , 7, 2269-2279		10
281	Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems. <i>Drug Safety</i> , 2018 , 41, 745-752	5.1	15
280	Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004-2015. 2018 , 5, 131-138		8
279	Signal Detection for Recently Approved Products: Adapting and Evaluating Self-Controlled Case Series Method Using a US Claims and UK Electronic Medical Records Database. <i>Drug Safety</i> , 2018 , 41, 523-536	5.1	9
278	Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. <i>Drug Safety</i> , 2018 , 41, 403-413	5.1	16
277	A prediction model-based algorithm for computer-assisted database screening of adverse drug reactions in the Netherlands. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 199-205	2.6	12
276	Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: What a clinician should know on disproportionality analysis of spontaneous reporting systems. 2018 , 28, 533-542		45
275	Extended likelihood ratio test-based methods for signal detection in a drug class with application to FDA's adverse event reporting system database. 2018 , 27, 876-890		7

274	Detection of drug-drug interactions through data mining studies using clinical sources, scientific literature and social media. 2018 , 19, 863-877		62
273	Local anesthetics systemic toxicity association with exparel (bupivacaine liposome)- a pharmacovigilance evaluation. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 581-587	4.1	24
272	An Alternative to Disproportionality: A Frequency-Based Method for Pharmacovigilance Data Mining. 2018 , 52, 294-299		1
271	GA-ADE: a novel approach based on graph algorithm to improves the detection of adverse drug events. 2018 , 77, 3493-3507		1
270	Assessing performance of sequential analysis methods for active drug safety surveillance using observational data. 2018 , 28, 668-681		0
269	Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors. <i>Drug Safety</i> , 2018 , 41, 357-361	5.1	90
268	Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System. <i>Drug Safety</i> , 2018 , 41, 313-320	5.1	13
267	An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 38-45	2.6	8
266	Detection of adverse drug reactions: evaluation of an automatic data processing applied in oncology performed in the French Diagnosis Related Groups database. 2018 , 32, 227-233		2
265	The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance. <i>Drug Safety</i> , 2018 , 41, 139-141	5.1	1
264	Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database. 2018 , 4, 32		11
263	Type B adverse drug reactions reported by an immunoallergology department. 2018 , 16, 1070		1
262	Response to "Comment on: Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database". <i>Clinical Drug Investigation</i> , 2018 , 38, 1199-1200	3.2	
261	Drug-induced tubulointerstitial nephritis in a retrospective study using spontaneous reporting system database. 2018 , 14, 1599-1604		10
260	Information-Derived Mechanistic Hypotheses for Structural Cardiotoxicity. 2018 , 31, 1119-1127		3
259	Drug-Induced Interstitial Lung Disease: A Systematic Review. 2018 , 7,		117
258	Masking by vaccines in pediatric drug safety signal detection in the EudraVigilance database. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1249-1256	2.6	1
257	Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System. 2018 , 273, 183-186		44

256	Application of biclustering algorithm in adverse drug reaction monitoring system of China. <i>Pharmacoepidemiology and Drug Safety</i> , 2018 , 27, 1257-1264	2.6	
255	Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab. <i>Drug Safety</i> , 2018 , 41, 1397-1410	5.1	20
254	Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database. <i>Clinical Drug Investigation</i> , 2018 , 38, 867-872	3.2	6
253	Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System. <i>Expert Opinion on Drug Safety</i> , 2018 , 17, 869-874	4.1	8
252	Crowdsourcing sugammadex adverse event rates using an in-app survey: feasibility assessment from an observational study. 2018 , 9, 331-342		7
251	From narrative descriptions to MedDRA: automagically encoding adverse drug reactions. 2018 , 84, 184-199		14
250	Exploring the Potential Routine Use of Electronic Healthcare Record Data to Strengthen Early Signal Assessment in UK Medicines Regulation: Proof-of-Concept Study. <i>Drug Safety</i> , 2018 , 41, 899-910	5.1	3
249	Pharmacovigilance of medicines for rare and ultrarare diseases. 2018 , 9, 631-638		11
248	Assessment of the Utility of Social Media for Broad-Ranging Statistical Signal Detection in Pharmacovigilance: Results from the WEB-RADR Project. <i>Drug Safety</i> , 2018 , 41, 1355-1369	5.1	29
247	Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database. 2018 , 4, 15		7
246	Detecting Pharmacovigilance Signals Combining Electronic Medical Records With Spontaneous Reports: A Case Study of Conventional Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis. <i>Frontiers in Pharmacology</i> , 2018 , 9, 875	5.6	13
245	Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004-2016. 2018 , 6, 2050312118777953		13
244	Safety of Biologics Approved for the Treatment of Rheumatoid Arthritis and Other Autoimmune Diseases: A Disproportionality Analysis from the FDA Adverse Event Reporting System (FAERS). 2018 , 32, 377-390		5
243	Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. 2019 , 10, 2042098619864744		7
242	A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. <i>Drug Safety</i> , 2019 , 42, 1365-1376	5.1	
241	Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. 2019 , 5, 1633-1635		52
240	Postpartum Bleeding in Pregnant Women Receiving SSRIs/SNRIs: New Insights From a Descriptive Observational Study and an Analysis of Data from the FAERS Database. 2019 , 41, 1755-1766		6
239	Adverse Drug Reaction Risk Measures: A Comparison of Estimates from Drug Surveillance and Randomised Trials. 2019 , 33, 331-339		3

238	Assessment of the cardiovascular adverse effects of drug-drug interactions through a combined analysis of spontaneous reports and predicted drug-target interactions. 2019 , 15, e1006851		5
237	Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. 2019 , 16, 1018-1022		19
236	Data Mining and Other Informatics Approaches to Pharmacoepidemiology. 2019 , 675-700		
235	Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). 2019 , 16, 1504-1509		11
234	Adverse reaction profiles of hemorrhagic adverse reactions caused by direct oral anticoagulants analyzed using the Food and Drug Administration Adverse Event Reporting System (FAERS) database and the Japanese Adverse Drug Event Report (JADER) database. 2019 , 16, 1295-1303		11
233	Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database. 2019 , 5, 21		
232	Pharmacovigilance Assessment of Drug-Induced Acute Pancreatitis Using a Spontaneous Reporting Database. 2019 , 38, 487-492		6
231	Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. 2019 , 84, 1097-1105		7
230	Medical device surveillance with electronic health records. 2019 , 2, 94		23
229	Tree-based scan statistic - Application in manufacturing-related safety signal detection. 2019 , 37, 49-55		2
228	Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database. <i>Clinical Drug Investigation</i> , 2019 , 39, 363-368	3.2	14
227	Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. <i>Clinical Drug Investigation</i> , 2019 , 39, 319-330	3.2	51
226	Exploring adverse drug reactions of diabetes medicine using social media analytics and interactive visualizations. 2019 , 48, 228-237		8
225	Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. 2019 , 8, 174-181		10
224	Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. 2019 , 16, 630-635		35
223	Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. 2019 , 44, 775-779		9
222	Time to onset in statistical signal detection revisited: A follow-up study in long-term onset adverse drug reactions. <i>Pharmacoepidemiology and Drug Safety</i> , 2019 , 28, 1283-1289	2.6	2
221	Comparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation Antipsychotics. 2019 , 13, 1178221819844205		12

220	Real-World Data Approaches for Early Detection of Potential Safety and Effectiveness Signals for Generic Substitution: A Metoprolol Extended-Release Case Study. 2019 , 59, 1275-1284		3
219	Suspected Adverse Drug Reactions Related to Breast Cancer Chemotherapy: Disproportionality Analysis of the Brazilian Spontaneous Reporting System. <i>Frontiers in Pharmacology</i> , 2019 , 10, 498	5.6	5
218	Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System. 2019 , 7, 2050312119836011		5
217	Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system. 2019 , 73, e13331		21
216	Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance-pharmacodynamic study. 2019 , 53,		21
215	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. 2019 , 14, 205-221		54
214	Evolving Roles of Spontaneous Reporting Systems to Assess and Monitor Drug Safety. 2019 ,		7
213	Evaluation of quantitative signal detection in EudraVigilance for orphan drugs: possible risk of false negatives. 2019 , 10, 2042098619882819		7
212	Concomitant febuxostat enhances methotrexate-induced hepatotoxicity by inhibiting breast cancer resistance protein. <i>Scientific Reports</i> , 2019 , 9, 20359	4.9	8
211	Safety Profile of Sclerosing Agents: An Analysis From the World Health Organization Pharmacovigilance Database VigiBase. 2019 , 45, 1517-1528		1
210	Pattern of adverse events induced by aflibercept and ranibizumab: A nationwide spontaneous adverse event reporting database, 2007-2016. 2019 , 98, e16785		2
209	Gabapentinoids and sleep apnea syndrome: a safety signal from the WHO pharmacovigilance database. 2019 , 42,		3
208	Pharmacoepidemiology in the Prevention of Adverse Drug Reactions. 2019 , 25-65		2
207	Signal Management and Methods of Signal Detection. 2019 , 13-29		
206	Myopathy with DPP-4 inhibitors and statins in the real world: investigating the likelihood of drug-drug interactions through the FDA adverse event reporting system. 2020 , 57, 71-80		14
205	Time-to-onset analysis of amiodarone-associated thyroid dysfunction. 2020 , 45, 65-71		4
204	Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). <i>Drug Safety</i> , 2020 , 43, 17-22	5.1	13
203	Comparison of signal detection of tumour necrosis factor- α inhibitors using the Korea Adverse Events Reporting System Database, 2005-2016. 2020 , 39, 347-355		4

202	Complementing Observational Signals with Literature-Derived Distributed Representations for Post-Marketing Drug Surveillance. <i>Drug Safety</i> , 2020 , 43, 67-77	5.1	2
201	Hypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS). <i>Drug Safety</i> , 2020 , 43, 363-369	5.1	4
200	Adverse Events Associated With Radium-223 in Metastatic Prostate Cancer: Disproportionality Analysis of FDA Data Reflecting Worldwide Utilization. 2020 , 18, 192-200.e2		6
199	Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System. 2020 , 31, 183-189		4
198	Potential for Detection of Safety Signals for Over-the-Counter Medicines Using National ADR Spontaneous Reporting Data: The Example of OTC NSAID-Associated Gastrointestinal Bleeding. 2020 , 8,		1
197	Hepatic adverse drug reactions in Malaysia: An 18-year review of the national centralized reporting system. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1669-1679	2.6	3
196	From Tumor Mutational Burden to Blood T Cell Receptor: Looking for the Best Predictive Biomarker in Lung Cancer Treated with Immunotherapy. 2020 , 12,		8
195	Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1689-1695	2.6	1
194	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. 2020 , 11, 4946		39
193	Impact of adverse event reports from marketing authorization holder-sponsored patient support programs on the performance of signal detection in pharmacovigilance. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 1357-1366	4.1	1
192	Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. 2020 , 1-7		6
191	Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. 2020 , 11, 2042098620938595		25
190	Risk of hepatitis B reactivation and cytomegalovirus related infections with Mogamulizumab: A retrospective study of international pharmacovigilance database. 2020 , 28, 100601		2
189	Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiology and Drug Safety</i> , 2020 , 29, 1279-1294	2.6	16
188	Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. 2020 , 21, 68		3
187	. 2020 ,		
186	A Deep Learning-Based Approach for Identifying the Medicinal Uses of Plant-Derived Natural Compounds. <i>Frontiers in Pharmacology</i> , 2020 , 11, 584875	5.6	5
185	The association of clozapine and haematological malignancies needs to be replicated by other studies and more importantly by analyses of subsamples from VigiBase. 2020 , 1-2		1

184	Molecular basis of mood and cognitive adverse events elucidated via a combination of pharmacovigilance data mining and functional enrichment analysis. 2020 , 94, 2829-2845		0
183	Pharmacovigilance of anti-cancer medicines: opportunities and challenges. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 849-860	4.1	2
182	A Pharmacovigilance Study of Hydroxychloroquine Cardiac Safety Profile: Potential Implication in COVID-19 Mitigation. 2020 , 9,		16
181	Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase. <i>Drug Safety</i> , 2020 , 43, 881-891	5.1	22
180	US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS). 2020 , 34, 135-140		4
179	Safety Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: A Disproportionality Analysis of FDA Adverse Event Reporting System. <i>Scientific Reports</i> , 2020 , 10, 4803	4.9	22
178	The potential role of big data in the detection of adverse drug reactions. 2020 , 13, 201-204		3
177	Association Between Antipsychotics and Osteoporosis Based on Real-World Data. 2020 , 54, 988-995		6
176	Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies. 2020 , 69, 683-687		9
175	The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database. 2020 , 44, 1021-1027		3
174	Adverse Drug Reactions during Real-Life Use of Direct Oral Anticoagulants in Italy: An Update Based on Data from the Italian National Pharmacovigilance Network. 2020 , 10, 266-276		8
173	A Disproportionality Analysis of the Adverse Drug Events Associated with Lurasidone in Paediatric Patients Using the US FDA Adverse Event Reporting System (FAERS). <i>Drug Safety</i> , 2020 , 43, 607-609	5.1	3
172	Lower odds of cardiac events for gonadotrophin-releasing hormone antagonists versus agonists. 2020 , 126, 9-10		4
171	Drug-induced vitiligo: a case/non-case study in Vigibase , the WHO pharmacovigilance database. 2020 , 34, 736-742		6
170	Evaluation of anti-infective-related -associated colitis using the Japanese Adverse Drug Event Report database. 2020 , 17, 921-930		3
169	Exploring Completeness of Adverse Event Reports as a Tool for Signal Detection in Pharmacovigilance. 2021 , 55, 142-151		0
168	Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. 2021 , 85, 229-232		0
167	Artificial Intelligence, Real-World Automation and the Safety of Medicines. <i>Drug Safety</i> , 2021 , 44, 125-133	3.1	14

166	Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride. 2021 , 157, 35-42		24
165	Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System. <i>Drug Safety</i> , 2021 , 44, 107-119	5.1	6
164	Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. 2021 , 47, 672-681		2
163	Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. 2021 , 186, 219-227		18
162	Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 1432-1442	3.8	26
161	Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System. 2021 , 90, 41-48		27
160	Improved Adverse Drug Event Prediction Through Information Component Guided Pharmacological Network Model (IC-PNM). 2021 , 18, 1113-1121		2
159	Differences in detected safety signals between benzodiazepines and non-benzodiazepine hypnotics: pharmacovigilance study using a spontaneous reporting system. 2021 , 18, 1130-1136		2
158	Tyrosine kinase inhibitors targeting vascular endothelial growth factor and the risk of aortic dissection-A pharmacovigilance analysis. 2021 , 9, e00707		3
157	Pharmacovigilance of Herbal Medicine: An Evolving Discipline. 2021 , 605-620		
156	Lung Cancer Adverse Events Reports for Angiotensin-Converting Enzyme Inhibitors: Data Mining of the FDA Adverse Event Reporting System Database. 2021 , 8, 594043		4
155	Risk comparison of beta-lactam-induced anaphylaxis: Therapeutic stratification analysis in a Vietnamese pharmacovigilance database. 2021 , 46, 950-956		1
154	Worsening of myasthenia due to antiepileptic, antipsychotic, antidepressant, and sedative medication: An estimation of risk based on reporting frequency. 2021 , 28, 2349-2356		1
153	Anaplastic lymphoma kinase tyrosine kinase inhibitor-induced hepatic failure in lung cancer patients: A study of signal mining and analysis of the FDA adverse event reporting system database. 2021 , 46, 1148-1154		0
152	Cardiovascular Safety Profile of Romosozumab: A Pharmacovigilance Analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). 2021 , 10,		10
151	Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System. 2021 , 13,		9
150	Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies. 2021 , 404, 113168		2
149	Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study. 2021 , 16, 471-483		5

148	Signal Detection of Adverse Drug Reactions of Cephalosporins Using Data from a National Pharmacovigilance Database. 2021 , 14,		2
147	Leveraging the Variability of Pharmacovigilance Disproportionality Analyses to Improve Signal Detection Performances. <i>Frontiers in Pharmacology</i> , 2021 , 12, 668765	5.6	4
146	Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis. 2021 , 149, 675-683		4
145	Nephrotoxicity in immune checkpoint inhibitor therapy: a pharmacovigilance study. 2021 ,		0
144	Cardiovascular toxicities associated with abiraterone compared to enzalutamide-A pharmacovigilance study. 2021 , 36, 100887		2
143	Data-driven methodology for discovery and response to pulmonary symptomology in hypertension through AI and machine learning: Application to COVID-19 related pharmacovigilance.		
142	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. 2021 , 8, 547-554		2
141	Analysis and Prediction of Adverse Reaction of Drugs with Machine Learning Models for Tracking the Severity. 1		0
140	The Impact of Serotonin Transporter Binding Affinity on the Risk of Bleeding Related to Antidepressants. 2021 , 41, 470-473		0
139	Real-world data-based adverse drug reactions detection from the Korea Adverse Event Reporting System databases with electronic health records-based detection algorithm. 2021 , 27, 14604582211033014		2
138	Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database. 2021 , 14, 3909-3927		20
137	Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). 2021 , 1		3
136	Safety profile of D-penicillamine: a comprehensive pharmacovigilance analysis by FDA adverse event reporting system. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 1443-1450	4.1	1
135	BRAF/MEK inhibitor-associated nephrotoxicity in a real-world setting and human kidney cells. 2021 , 32, 1076-1083		1
134	Disproportionality analysis of reported drug adverse events to assess a potential safety signal for pentavalent vaccine in 2019 in El Salvador. 2021 , 39, 4849-4855		0
133	Signal detection of drospirenone-containing oral contraceptives: a disproportionality analysis using the Korea Adverse Event Reporting System Database, 2008-2017. <i>BMJ Open</i> , 2021 , 11, e045948	3	0
132	Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. 2021 , 22,		9
131	A Network Analysis of Drug Combinations Associated with Acute Generalized Exanthematous Pustulosis (AGEP). 2021 , 10,		1

130	Bevacizumab and gastrointestinal perforations: a review from the FDA Adverse Event Reporting System (FAERS) database. 2021 , 54, 1290-1297		3
129	Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: a disproportionality analysis from the WHO pharmacovigilance database. 2021 , 58,		2
128	Assessment of pancreatitis associated with tocilizumab use using the United States Food and Drug Administration Adverse Event Reporting System database. <i>Scientific Reports</i> , 2021 , 11, 18818	4.9	1
127	High prevalence of spin was found in pharmacovigilance studies using disproportionality analyses to detect safety signals: a meta-epidemiological study. 2021 , 138, 73-79		3
126	A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases. 2021 , 139, 191-198		3
125	Machine Learning for Detection of Safety Signals From Spontaneous Reporting System Data: Example of Nivolumab and Docetaxel. <i>Frontiers in Pharmacology</i> , 2020 , 11, 602365	5.6	4
124	Statistics: Analysis and Presentation of Safety Data. 349-388		3
123	A quantitative analysis of the spontaneous reporting of congestive heart failure-related adverse events with systemic anti-fungal drugs. 2013 , 53, 762-72		9
122	A Deep Learning Based Named Entity Recognition Approach for Adverse Drug Events Identification and Extraction in Health Social Media. 2017 , 237-248		6
121	Quantity is not enough: completeness of suspected adverse drug reaction reports in Spain-differences between regional pharmacovigilance centres and pharmaceutical industry. 2020 , 76, 1175-1181		5
120	Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations. <i>Drug Safety</i> , 2020 , 43, 479-487	5.1	21
119	Exploration of the association rules mining technique for the signal detection of adverse drug events in spontaneous reporting systems. 2012 , 7, e40561		20
118	Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 2013 , 8, e81208		39
117	Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe. 2015 , 10, e0119551		36
116	Factors Affecting the Timing of Signal Detection of Adverse Drug Reactions. 2015 , 10, e0144263		7
115	Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. 2017 , 12, e0190102		25
114	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. 2020 , 8, e17353		4
113	Automatically Recognizing Medication and Adverse Event Information From Food and Drug Administration's Adverse Event Reporting System Narratives. 2014 , 2, e10		16

112	Improved Detection Criteria for Detecting Drug-Drug Interaction Signals Using the Proportional Reporting Ratio. 2020 , 14,	3
111	Azithromycin and risk of sudden cardiac death: guilty as charged or falsely accused?. 2013 , 80, 539-44	29
110	Gender Effects on Statin-Associated Muscular Adverse Events: An Analysis of the FDA AERS Database. 2013 , 04, 340-346	2
109	Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database. 2014 , 6, 601-12	48
108	Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model. 2016 , 4, e1753	5
107	Pharmacovigilance Bibliometrics: Visualizing Thematic Development in the Category of Pharmacology and Pharmacy in Web of Science. <i>Frontiers in Pharmacology</i> , 2021 , 12, 731757	5.6 2
106	Antifungal therapy with azoles induced the syndrome of acquired apparent mineralocorticoid excess: A literature and database analysis. 2021 , AAC0166821	2
105	Cardiotoxicity in Biological Agent-Targeted Therapy for Rheumatoid Arthritis: ADR Signal Mining and Analysis of Food and Drug Administration Adverse Event Reporting System Database. 2021 , 9, 716648	
104	Safety of medicines and vaccines - building next generation capability. 2021 , 42, 1051-1063	3
103	Adverse Cardiovascular and Pulmonary Events Associated With Chimeric Antigen Receptor T-Cell Therapy. 2021 , 78, 1800-1813	11
102	Comparing Data-Mining Algorithms Developed for Longitudinal Observational Databases.	1
101	Current Issues in Drug Regulation. 2016 , 19-31	
100	Assessment of the cardiovascular adverse effects of drug-drug interactions through a combined analysis of spontaneous reports and predicted drug-target interactions.	
99	aer2vec: Distributed Representations of Adverse Event Reporting System Data as a Means to Identify Drug/Side-Effect Associations.	1
98	Contraceptive counseling about adverse reactions of intrauterine contraception: Exploration of narratives found in web-based discussion boards. 2022 , 104, 103166	
97	Analysis of Data on Adverse Drug Events Reported to the Food and Drugs Administration of the United States of America. 2020 , 10, 203-227	0
96	Patterns of Spontaneous Adverse Events Reporting on Human Papillomavirus Vaccines according to the Applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017. 2020 , 30, 19-30	2
95	Do contemporary antiretrovirals increase the risk of end-stage liver disease? Signals from patients starting therapy in the North American AIDS Cohort Collaboration on Research and Design. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 ,	2.6 1

94	Interactive exploration of population scale pharmacoepidemiology datasets. 2020 ,		
93	Statistical Mining of Potential Drug Interaction Adverse Effects in FDA's Spontaneous Reporting System. 2010 , 2010, 281-5		28
92	Analyzing patterns of drug use in clinical notes for patient safety. 2012 , 2012, 63-70		15
91	Using temporal patterns in medical records to discern adverse drug events from indications. 2012 , 2012, 47-56		22
90	Translational bioinformatics embraces big data. 2012 , 7, 130-4		19
89	tcTKB: an integrated cardiovascular toxicity knowledge base for targeted cancer drugs. 2015 , 2015, 1342-51		1
88	: Distributed Representations of Adverse Event Reporting System Data as a Means to Identify Drug/Side-Effect Associations. 2019 , 2019, 717-726		3
87	Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database. <i>British Journal of Clinical Pharmacology</i> , 2021 ,	3.8	1
86	Identification of TMB, CD8 T-cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit-toxicity ratio of anti-PD-1/PD-L1 therapy. 2021 , 11, e598		
85	Hepatotoxicity-Related Adverse Effects of Proton Pump Inhibitors: A Cross-Sectional Study of Signal Mining and Analysis of the FDA Adverse Event Report System Database. 2021 , 8, 648164		3
84	Risk of pregabalin-induced hypoglycemia: Analysis of the Japanese Adverse Event Report database. 2021 ,		0
83	Data-driven methodology for discovery and response to pulmonary symptomology in hypertension through statistical learning and data mining: Application to COVID-19 related pharmacovigilance. 2021 , 10,		1
82	Special Applications of Pharmacoepidemiology. 2021 , 387-463		
81	Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy.. <i>Frontiers in Pharmacology</i> , 2021 , 12, 797852	5.6	1
80	TEDAR: Temporal dynamic signal detection of adverse reactions. 2021 , 122, 102212		
79	Analysis of Neurological Adverse Events Reported in VigiBase From COVID-19 Vaccines.. 2022 , 14, e21376		0
78	The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study.. 2022 , 56, 323		
77	Cutaneous Toxicity Associated With Enfortumab Vedotin: A Real-World Study Leveraging U.S. Food and Drug Administration Adverse Event Reporting System.. 2021 , 11, 801199		1

76	A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.. 2022 ,		1
75	Risk assessment of micafungin-induced liver injury using spontaneous reporting system data and electronic medical records.. 2022 ,		0
74	Time until onset of acute kidney injury by combination therapy with "Triple Whammy" drugs obtained from Japanese Adverse Drug Event Report database.. 2022 , 17, e0263682		1
73	Atenolol and mortality events in patients with chronic kidney disease: analysis of data from the Japanese Adverse Drug Event Report database.. 2022 ,		
72	Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.. 2022 ,		
71	Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 851246	5.6	0
70	Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 858279	5.6	2
69	Enhancer RNA-based modeling of adverse events and objective responses of immunotherapy.		
68	Hyperglycaemic disorders associated with PCSK9 inhibitors: a real-world, pharmacovigilance study.. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	0
67	Hypoglycemia associated with direct-acting anti-hepatitis C virus drugs: An epidemiologic surveillance study of the FDA adverse event reporting system (FAERS).. <i>Clinical Endocrinology</i> , 2021	3.4	0
66	Image_1.JPEG. 2018 ,		
65	Image_2.JPEG. 2018 ,		
64	Image_3.JPEG. 2018 ,		
63	Image_4.JPEG. 2018 ,		
62	Table_1.DOCX. 2018 ,		
61	Analysis of the frequency of ceftriaxone-induced encephalopathy using the Japanese Adverse Drug Event Report database.. <i>International Journal of Clinical Pharmacy</i> , 2022 , 1	2.3	0
60	Analysis of the adverse nervous system and gastrointestinal events associated with solifenacin in older adults using the US FDA adverse event reporting system.. <i>International Journal of Risk and Safety in Medicine</i> , 2022 ,	1.6	
59	Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database.. <i>Scientific Reports</i> , 2022 , 12, 7140	4.9	2

58	Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.. <i>Journal of Headache and Pain</i> , 2022 , 23, 53	8.8	o
57	Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 63, 103832	4	
56	Black Swan Events and Intelligent Automation for Routine Safety Surveillance.. <i>Drug Safety</i> , 2022 , 45, 419-427	5.1	o
55	Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.. <i>Drug Safety</i> , 2022 , 45, 571-582	5.1	o
54	Machine Learning in Causal Inference: Application in Pharmacovigilance.. <i>Drug Safety</i> , 2022 , 45, 459-476	5.1	o
53	Cardiac disorder-related adverse events for aryl hydrocarbon receptor agonists: a safety review.. <i>Expert Opinion on Drug Safety</i> , 2022 ,	4.1	o
52	Methodological approaches for medication error analyses in patient safety and pharmacovigilance reporting systems: a scoping review protocol. <i>BMJ Open</i> , 2022 , 12, e057764	3	o
51	Engaging Patients via Online Healthcare Fora: Three Pharmacovigilance Use Cases. <i>Frontiers in Pharmacology</i> , 13,	5.6	o
50	Analyzing excipient-related adverse events in antiseizure drug formulations. <i>Epilepsy Research</i> , 2022 , 184, 106947	3	
49	Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. <i>Journal of Central Nervous System Disease</i> , 2022 , 14, 117957352211096	4.4	
48	COVID-19 Vaccine-Associated Transient Global Amnesia: A Disproportionality Analysis of the WHO Safety Database. <i>Frontiers in Pharmacology</i> , 13,	5.6	
47	A database of pediatric drug effects to evaluate ontogenic mechanisms from child growth and development. <i>Med</i> , 2022 ,	31.7	
46	Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system. <i>Pharmacoepidemiology and Drug Safety</i> ,	2.6	o
45	Hypnotics and infections: disproportionality analysis of the FDA adverse event reporting system database. <i>Journal of Clinical Sleep Medicine</i> ,	3.1	
44	Contrast Media Adverse Drug Reactions in Highly Polluted Environment. <i>International Journal of Environmental Research and Public Health</i> , 2022 , 19, 7077	4.6	
43	Thromboembolic Events While Taking Direct Oral Anticoagulants: An Analysis of Post-market WHO Database Reports from 2012 to 2020. <i>Clinical Drug Investigation</i> , 2022 , 42, 593-598	3.2	
42	Identifying new drugs associated with pulmonary arterial hypertension: A WHO pharmacovigilance database disproportionality analysis. <i>British Journal of Clinical Pharmacology</i> ,	3.8	o
41	Patient reporting of sexual adverse events on an online platform for medication experiences. <i>British Journal of Clinical Pharmacology</i> ,	3.8	

40	Anaplastic lymphoma kinase tyrosine kinase inhibitors associated gastrointestinal obstruction, perforation, and ulceration: an analysis of the FDA adverse event reporting system database (FAERS). <i>International Journal of Clinical Pharmacy</i> ,	2.3	0
39	Historical profile will tell? A deep learning-based multi-level embedding framework for adverse drug event detection and extraction. <i>Decision Support Systems</i> , 2022 , 160, 113832	5.6	
38	Pulmonary adverse events associated with hypertension in non-small cell lung cancer patients receiving PD-1/PD-L1 inhibitors. 13,		0
37	Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. 2022 , 7,		2
36	Identifying the Patterns of Adverse Drug Responses of Cetuximab. 2022 , 32, 226-237		0
35	Detecting early safety signals of infliximab using machine learning algorithms in the Korea adverse event reporting system. 2022 , 12,		0
34	Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019.		0
33	Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database. 1-8		0
32	Network Analysis for Signal Detection in Spontaneous Adverse Event Reporting Database: Application of Network Weighting Normalization to Characterize Cardiovascular Drug Safety.		0
31	Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database. 2022 , 12,		0
30	Hepatobiliary calculi associated with ceftriaxone treatment: An analysis of FAERS data from 2004 to 2021. 2022 ,		0
29	Methods for drug safety signal detection using routinely collected observational electronic health care data: A systematic review.		0
28	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. 2022 , 17, e0272022		1
27	Linezolid and the risk of QT interval prolongation: A Pharmacovigilance Study of the Food and Drug Administration Adverse Event Reporting System.		1
26	Progressive Multifocal Leukoencephalopathy in Patients Treated With Chimeric Antigen Receptor T-Cells.		0
25	Causality Discovery Based on Combined Causes and Multiple Causes in Drug-Drug Interaction. 2022 , 53-66		0
24	Antipsychotic Abuse, Dependence, and Withdrawal in the Pediatric Population: A Real-World Disproportionality Analysis. 2022 , 10, 2972		0
23	Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy. 13,		0

- 22 A Fundamental Question of Counting in Association Rules. ○
- 21 Drug-induced liver injury following the use of tocilizumab or sarilumab in patients with coronavirus disease 2019. **2022**, 22, ○
- 20 Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks. ○
- 19 Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS). 10, ○
- 18 Pharmacovigilance Analysis of Heart Failure Associated With Anti-HER2 Monotherapies and Combination Regimens for Cancer. **2023**, ○
- 17 The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (≥75 years): a retrospective, pharmacovigilance study. **2023**, 22, ○
- 16 Data mining techniques for detecting signals of adverse drug reaction of cardiac therapy drugs based on Jinan adverse event reporting system database: a retrospective study. **2023**, 13, e068127 ○
- 15 Enhancer RNA-based modeling of adverse events and objective responses of cancer immunotherapy reveals associated key enhancers and target genes. 12, ○
- 14 Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System. **2023**, ○
- 13 Methotrexate-related adverse events and impact of concomitant treatment with folic acid and tumor necrosis factor-alpha inhibitors: An assessment using the FDA adverse event reporting system. 14, ○
- 12 Artificial intelligence and pharmacovigilance: what is happening, what could happen and what should happen?. **2023**, 100743 ○
- 11 A post-marketing pharmacovigilance study of avapritinib: Adverse event data mining and analysis based on the United States Food and Drug Administration Adverse Event Reporting System database. ○
- 10 An industry perspective on the use of machine learning in drug and vaccine safety. 3, ○
- 9 Thromboembolism profiles associated with cyclin-dependent kinase 4/6 inhibitors: a real-world pharmacovigilance study and a systematic review. 1-11 ○
- 8 Everyday Evaluation of Herb/Dietary Supplement-Drug Interaction: A Pilot Study. **2023**, 10, 20 ○
- 7 Exploring the impact of design criteria for reference sets on performance evaluation of signal detection algorithms: The case of drug-drug interactions. ○
- 6 Neurotoxicity induced by taxane-derived drugs: analysis of the FAERS database 2017-2021. 1-10 ○
- 5 Bayesian generalized linear low rank regression models for the detection of vaccine-adverse event associations. ○

- 4 Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase[®], the WHO Pharmacovigilance Database. **2023**, 15, 2041
- 3 Signal detection of COVID -19 vaccines adverse events using spontaneous reports from South Korea.
- 2 Association between methotrexate-induced Stevens-Johnson syndrome/toxic epidermal necrolysis and furosemide: a real-world disproportionality analysis. 1-8
- 1 Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. **2023**, 59, 101967